Emerging data suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , may offer a significant advancement for obesity management . Preliminary human trials have indicated impressive decreases in visceral fat , potentially outperforming existing obesity medications . Despite this, more study is needed to completely determine its susta